Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

a technology of regulatory t cells and molecules, applied in the field of molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases, can solve the problems of autoimmune diseases, invasiveness, and inability to meet the needs of patients' own t cells, and achieve the effects of prolonging the circulating half-life, and increasing the molecular size of fusion proteins
US20170204154A1Inactive Publication Date: 2017-07-20DELINIA
0 Cites 16 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
DELINIA
Publication Date
2017-07-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2αβγ form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
Need to check novelty before this filing date? Find Prior Art

Description

REFERENCE TO A SEQUENCE LISTING

[0001] The Sequence Listing written in file SequenceListing_097584-000400US_ST25.txt created on May 3, 2016, 88,573 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference in its entirety for all purposes.BACKGROUND OF THE INVENTION

[0002] The immune system must be able to discriminate between self and non-self. When self / non-self discrimination fails, the immune system destroys cells and tissues of the body and as a result causes autoimmune diseases. Regulatory T cells actively suppress activation of the immune system and prevent pathological self-reactivity and consequent autoimmune disease. Developing drugs and methods to selectively activate regulatory T cells for the treatment of autoimmune disease is the subject of intense research and, until the development of the present invention, has been largely unsuccessful.

[0003] Regulatory T cells (Treg) are a class of CD4+CD25+ T cells that suppress the activity of othe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More